Oppenheimer analyst Jay Olson maintains $Marinus Pharmaceuticals (MRNS.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 38.6% and a total average return of 12.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Marinus Pharmaceuticals (MRNS.US)$'s main analysts recently are as follows:
Marinus Pharmaceuticals' Phase III study of oral ganaxolone in tuberous sclerosis complex rare epilepsy did not achieve the primary endpoint, failing to show a significant difference in placebo-adjusted percent change. Despite this, the company may still find 'leverageability' in its revenue stream from CDD. Following the stock's significant decline, there could potentially be an arbitrage opportunity.
The revision of the outlook on Marinus Pharmaceuticals to a more cautious stance comes in the wake of the Phase III trial of ganaxolone in tuberous sclerosis complex not achieving its primary endpoint. This outcome is coupled with the company's reported financial limitations and the indeterminate schedule for future actions.
Marinus Pharmaceuticals' Phase III trial of oral ganaxolone in treating tuberous sclerosis complex, a type of rare epilepsy, did not achieve its primary goal of reducing seizures. With no immediate catalysts anticipated until 2025, the outlook on the company has become more conservative.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奧本海默控股分析師Jay Olson維持$Marinus Pharmaceuticals (MRNS.US)$買入評級。
根據TipRanks數據顯示，該分析師近一年總勝率為38.6%，總平均回報率為12.4%。
此外，綜合報道，$Marinus Pharmaceuticals (MRNS.US)$近期主要分析師觀點如下：
馬林納斯製藥在腎臟硬化症罕見癲癇病患者中口服加樂胺的三期研究未能達到主要終點，未顯示出與安慰劑調整的百分比變化有顯著差異。儘管如此，公司仍可能從CDD的營業收入中找到"槓桿效應"。在股價急劇下跌後，可能存在套戥機會。
將馬林納斯製藥的展望調整爲更加謹慎的立場，是因爲在腎臟硬化症中加樂胺的三期試驗未能實現其主要終點。這一結果與公司報告的財務限制和未來行動的不確定時間表相結合。
馬林納斯製藥在治療腎臟硬化症的口服加樂胺三期試驗未能實現減少癲癇發作的主要目標。預計直到2025年都沒有即時催化劑，公司前景變得更加保守。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
